Biologics and Biosimilars

Almost one decade back the first biosimilars was launched in Europe. Now they have 15 biosimilars and all are well accepted since

high price branded biologics were tough to reach by many patients. Recently biosimilars has been endorsed everywhere in the

world starting from developing to developed countries. United States Food and Drug Administration (USFDA) approved the first

biosimilars in 2015 and currently they have 03 biosimilars which are playing pivotal role in price cutting of branded biologics. They

also have many biosimilars to be launched shortly. Australia, Canada, Africa and Asia are also aggressive with biosimilars specially

India, Korea, China made remarkable effort in biosimilars. However, considering the changes in disease pattern, increasing use of

biological drugs, huge number of population, rising health awareness, recent economic growth, success history of some biologic

companies, dependence on generic items, price sensitivity, relax regulation, growing health budget, very low production cost and

other relevant factors, Asia is an important hub for biosimilars. Therefore, this study found out the prospects of biosimilars in Asia.